Delivery System
for Pain Management
Chronic Pain syndromes have strong impact on the patients’ physical and mental conditions and take a toll on their functional capabilities. Cannabis has been shown to be effective in pain management and patients report a significant improvement in their general wellbeing.
Smoking and inhalation are currently the most commonly used methods for administering medical cannabis. However, the precise concentration of active cannabinoids in inflorescences is inconsistent and difficult to determine. In addition, smoking may have deleterious side effects and social acceptance issues, which may reduce compliance of drug administration.
OWC is developing a cannabinoid-enriched sublingual disintegrating tablet to provide patients who suffer from chronic pain syndromes with a validated and consistent form of drug administration. Such an administration modality will allow for dose adjustment and offer a healthier alternative to smoking. The tablet will be available in various ratios and strengths of CBD/THC in order to achieve optimal efficacy and tolerability.
The following milestones have been completed:
• Development of a second generation tablet formulation has been completed and patent protection has been applied for.
• A Phase I safety and a PK study will be conducted at a leading medical center in Tel Aviv in the first quarter of 2019 as smoking/inhalation substitute
• OWC has obtained a permit from the Israel Medical Cannabis Authority (IMCA) to conduct an efficacy study on chronic pain patients and is filing for an IRB approval in order to initiate the study.
RELATED ARTICLES
OWC Pharmaceutical Research Corp Successfully Tests Unique, Innovative Delivery Formulation Aimed at Multiple Myeloma Therapy.
Our newly developed, highly concentrated formulation, OWC-1808, was administered in vivo for the first time and was found to be safe and tolerable. This formulation will allow the delivery of very high doses of CBD and THC with exceptional bioavailability, and will be directed initially at our ongoing program for treating Multiple Myeloma.
OWC Pharmaceutical Research Corp. to report progress in clinical trials for ointment care for skin diseases.
The first ever safety study of cannabis-based topical ointment, conducted at Sheba Academic Medical Center, is close to completion as the last healthy volunteer started the treatment three weeks ago. The study is expected to be completed by the end of December 2018.
OWC Pharmaceutical Research Corp Completes Development of Next Generation Orally-Disintegrating Tablet.
OWC Pharmaceutical has completed the pre-clinical development of its next generation, orally-disintegrating tablet containing cannabis extract with specific amounts of the cannabinoids tetrahydrocannabinol (“THC”) and cannabidiol (“CBD”). The tablet is targeted at different indications and will be available in various ratios of THC to CBD and various doses of these actives.
